Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

Aharonowiz, 2008, Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis, PLoS One, 3, e3145, 10.1371/journal.pone.0003145 Alvarez, 2008, Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets, Pediatr. Res., 64, 653, 10.1203/PDR.0b013e318186e5dd Arévalo-Martin, 2003, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, J. Neurosci., 23, 2511, 10.1523/JNEUROSCI.23-07-02511.2003 Baker, 2000, Cannabinoids control spasticity and tremor in a multiple sclerosis model, Nature, 404, 84, 10.1038/35003583 Baker, 2001, Endocannabinoids control spasticity in experimental multiple sclerosis, FASEB J., 15, 300, 10.1096/fj.00-0399fje Baker, 2008, The endocannabinoid system and multiple sclerosis, Curr. Pharm. Des, 14, 2326, 10.2174/138161208785740036 Baker, 2007, Cannabinoid control of neuroinflammation related to multiple sclerosis, Br. J. Pharmacol., 152, 649, 10.1038/sj.bjp.0707458 Balabanov, 2007, Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis, J. Neurosci., 27, 2013, 10.1523/JNEUROSCI.4689-06.2007 Baraczka, 2003, Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis, Acta Microbiol. Immunol. Hung, 50, 339, 10.1556/AMicr.50.2003.4.3 Barnes, 2006, Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain, Expert Opin. Pharmacother., 7, 607, 10.1517/14656566.7.5.607 Basso, 2008, Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis, J. Clin. Invest., 118, 1532, 10.1172/JCI33464 Benito, 2007, Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis, J. Neurosci., 27, 2396, 10.1523/JNEUROSCI.4814-06.2007 British Medical Association Report, 1997 Brooks, 2002, Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors, Eur. J. Pharmacol., 439, 83, 10.1016/S0014-2999(02)01369-9 Brück, 2005, The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage, J. Neurol., 252, v3 Cabranes, 2005, Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis, Neurobiol. Dis., 20, 207, 10.1016/j.nbd.2005.03.002 Cabranes, 2006, Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice, Brain Res., 1107, 199, 10.1016/j.brainres.2006.06.001 Centonze, 2007, The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis, Brain, 130, 2543, 10.1093/brain/awm160 Centonze, 2009, Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis, J. Neurosci., 29, 3442, 10.1523/JNEUROSCI.5804-08.2009 Collin, 2007, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis, Eur. J. Neurol., 4, 290, 10.1111/j.1468-1331.2006.01639.x Collin, 2010, A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis, Neurol. Res., 32, 451, 10.1179/016164109X12590518685660 Consroe, 1997, The perceived effects of smoked cannabis on patient with multiple sclerosis, Exp. Neurol., 38, 44 Croxford, 2003, Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212, J. Clin. Invest., 111, 1231, 10.1172/JCI200317652 Croxford, 2008, Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis, J. Neuroimmunol, 193, 120, 10.1016/j.jneuroim.2007.10.024 de Lago, 2004, In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake, Eur. J. Pharmacol., 484, 249, 10.1016/j.ejphar.2003.11.027 de Lago, 2006, UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders, Eur. Neuropsychopharmacol., 16, 7, 10.1016/j.euroneuro.2005.06.001 de Lago, 2010, Cannabinoids, multiple sclerosis and neuroprotection, Expert Rev. Clin. Pharmacol., 2, 645, 10.1586/ecp.09.42 Di Filippo, 2008, Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis, J. Neurol. Neurosurg. Psychiatry, 79, 1224, 10.1136/jnnp.2007.139071 Docagne, 2007, Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation, Mol. Cell Neurosci., 34, 551, 10.1016/j.mcn.2006.12.005 Docagne, 2008, Therapeutic potential of CB2 targeting in multiple sclerosis, Expert Opin. Ther. Targets, 12, 185, 10.1517/14728222.12.2.185 Downer, 2011, Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis, J. Biol. Chem., 286, 10316, 10.1074/jbc.M110.188599 Eljaschewitsch, 2006, The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells, Neuron, 49, 67, 10.1016/j.neuron.2005.11.027 Farias, 2007, Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination, Neuroimmunomodulation, 14, 32, 10.1159/000107286 Fernández-Ruiz, 2005, Cannabinoids in neurodegeneration and neuroprotection, 79 Fernández-Ruiz, 2007, Cannabinoid CB2 receptor: a new target for controlling neural cell survival?, Trends Pharmacol. Sci., 28, 39, 10.1016/j.tips.2006.11.001 Fernández-Ruiz, 2010, The endocannabinoid system as a target for the treatment of neuronal damage, Expert Opin. Ther. Targets, 14, 387, 10.1517/14728221003709792 Frohman, 2003, Multiple sclerosis, Med. Clin. North Am., 87, 867, 10.1016/S0025-7125(03)00008-7 Gonsette, 2008, Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity, J. Neurol. Sci., 274, 48, 10.1016/j.jns.2008.06.029 Hasseldam, 2010, Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis, Neuroimmunomodulation, 17, 252, 10.1159/000290041 Jackson, 2004, Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture, Eur. J. Neurosci., 20, 2267, 10.1111/j.1460-9568.2004.03711.x Jackson, 2005, Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation, Neuroscience, 134, 261, 10.1016/j.neuroscience.2005.02.045 Jean-Gilles, 2009, Plasma endocannabinoid levels in multiple sclerosis, J. Neurol. Sci., 287, 212, 10.1016/j.jns.2009.07.021 Kmietowicz, 2010, Cannabis based drug is licensed for spasticity in patients with MS, BMJ, 340, c3363, 10.1136/bmj.c3363 Kubajewska, 2010, Cannabinoids and experimental models of multiple sclerosis, Immunobiology, 215, 647, 10.1016/j.imbio.2009.08.004 Lakhan, 2009, Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review, BMC Neurol., 9, 59, 10.1186/1471-2377-9-59 Loría, 2010, An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis, Neurobiol. Dis., 37, 166, 10.1016/j.nbd.2009.09.020 Lowry, 1951, Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 Maresz, 2007, Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells, Nat. Med., 13, 492, 10.1038/nm1561 Martino, 1997, Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis, J. Neurol. Sci., 152, 51, 10.1016/S0022-510X(97)00142-1 Melanson, 2009, Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia, Mult. Scler., 15, 1135, 10.1177/1352458509106856 Mendel, 1995, A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells, Eur. J. Immunol., 25, 1951, 10.1002/eji.1830250723 Mestre, 2005, Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis, J. Neurochem., 92, 1327, 10.1111/j.1471-4159.2004.02979.x Mestre, 2009, A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules, Mol. Cell Neurosci., 40, 258, 10.1016/j.mcn.2008.10.015 Mitosek-Szewczyk, 2008, Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis, Neuroscience, 155, 45, 10.1016/j.neuroscience.2008.05.025 Molina-Holgado, 1999, N-Acetyl-cysteine inhibition of encephalomyelitis Theiler's virus-induced nitric oxide and tumour necrosis factor-alpha production by murine astrocyte cultures, Biofactors, 10, 187, 10.1002/biof.5520100215 Ohgoh, 2002, Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis, J. Neuroimmunol, 125, 170, 10.1016/S0165-5728(02)00029-2 Ortega-Gutiérrez, 2005, Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis, FASEB J., 19, 1338, 10.1096/fj.04-2464fje Pawlak, 2005, Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen, Mol. Brain Res., 138, 1, 10.1016/j.molbrainres.2004.10.043 Pertwee, 2002, Cannabinoids and multiple sclerosis, Pharmacol. Ther., 95, 165, 10.1016/S0163-7258(02)00255-3 Pertwee, 2007, Cannabinoids and multiple sclerosis, Mol. Neurobiol., 36, 45, 10.1007/s12035-007-0005-2 Pryce, 2003, Cannabinoids inhibit neurodegeneration in models of multiple sclerosis, Brain, 126, 2191, 10.1093/brain/awg224 Pryce, 2005, Emerging properties of cannabinoid medicines in management of multiple sclerosis, Trends Neurosci., 28, 272, 10.1016/j.tins.2005.03.006 Pryce, 2007, Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors, Br. J. Pharmacol., 150, 519, 10.1038/sj.bjp.0707003 Rog, 2005, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, Neurology, 65, 812, 10.1212/01.wnl.0000176753.45410.8b Rog, 2010, Cannabis-based medicines in multiple sclerosis–a review of clinical studies, Immunobiology, 215, 658, 10.1016/j.imbio.2010.03.009 Schroder, 2009, Estrogen modulates expression of putative housekeeping genes in the mouse uterus, Endocrine, 35, 211, 10.1007/s12020-009-9154-6 Shibaki, 2002, Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant, Exp. Dermatol., 11, 126, 10.1034/j.1600-0625.2002.110204.x Stadelmann, 2011, Inflammation, demyelination, and degeneration - recent insights from MS pathology, Biochim. Biophys. Acta, 1812, 275, 10.1016/j.bbadis.2010.07.007 Tanuma, 1997, Competitive PCR quantification of pro- and anti-inflammatory cytokine mRNA in the central nervous system during autoimmune encephalomyelitis, J. Neuroimmunol, 73, 197, 10.1016/S0165-5728(96)00199-3 Tilleux, 2007, Neuroinflammation and regulation of glial glutamate uptake in neurological disorders, J. Neurosci. Res., 85, 2059, 10.1002/jnr.21325 Trapp, 2008, Multiple sclerosis: an immune or neurodegenerative disorder?, Annu. Rev. Neurosci., 31, 247, 10.1146/annurev.neuro.30.051606.094313 Tumani, 2009, Cerebrospinal fluid biomarkers in multiple sclerosis, Neurobiol. Dis., 35, 117, 10.1016/j.nbd.2009.04.010 Vallejo-Illarramendi, 2006, Increased expression and function of glutamate transporters in multiple sclerosis, Neurobiol. Dis., 21, 154, 10.1016/j.nbd.2005.06.017 Vaney, 2004, Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study, Mult. Scler., 10, 417, 10.1191/1352458504ms1048oa Vercellino, 2007, Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage, J. Neuropathol. Exp. Neurol., 66, 732, 10.1097/nen.0b013e31812571b0 Villarroya, 1997, Expression of TNF alpha in central neurons of Lewis rat spinal cord after EAE induction, J. Neurosci. Res., 49, 592, 10.1002/(SICI)1097-4547(19970901)49:5<592::AID-JNR9>3.0.CO;2-6 Wade, 2006, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis, Mult. Scler., 12, 639, 10.1177/1352458505070618 Wildbaum, 1999, Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis, Gene Ther., 6, 1128, 10.1038/sj.gt.3300915 Witting, 2006, Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection, PNAS (USA), 103, 6362, 10.1073/pnas.0510418103 Wright, 2007, Cannabinoid-based medicines for neurological disorders—clinical evidence, Mol. Neurobiol., 36, 129, 10.1007/s12035-007-0003-4 Yiangou, 2006, COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurol., 6, 12, 10.1186/1471-2377-6-12 Zajicek, 2003, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, Lancet, 362, 1517, 10.1016/S0140-6736(03)14738-1 Zajicek, 2005, Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up, J. Neurol. Neurosurg. Psychiatry, 76, 1664, 10.1136/jnnp.2005.070136